GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OptiNose Inc (NAS:OPTN) » Definitions » Change In Inventory

OptiNose (OptiNose) Change In Inventory : $1.29 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is OptiNose Change In Inventory?

OptiNose's change in inventory for the quarter that ended in Dec. 2023 was $-0.06 Mil. It means OptiNose's inventory increased by $0.06 Mil from Sep. 2023 to Dec. 2023 .

OptiNose's change in inventory for the fiscal year that ended in Dec. 2023 was $1.29 Mil. It means OptiNose's inventory declined by $1.29 Mil from Dec. 2022 to Dec. 2023 .

OptiNose's Total Inventories for the quarter that ended in Dec. 2023 was $8.05 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. OptiNose's Days Inventory for the quarter that ended in Dec. 2023 was 344.60.

Inventory Turnover measures how fast the company turns over its inventory within a year. OptiNose's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.26.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. OptiNose's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.41.


OptiNose Change In Inventory Historical Data

The historical data trend for OptiNose's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptiNose Change In Inventory Chart

OptiNose Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Inventory
Get a 7-Day Free Trial Premium Member Only 3.76 -5.43 -2.71 2.49 1.29

OptiNose Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 1.12 0.55 -0.32 -0.06

OptiNose Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OptiNose  (NAS:OPTN) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

OptiNose's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=8.0475/2.131*365 / 4
=344.60

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

OptiNose's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

OptiNose's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OptiNose Change In Inventory Related Terms

Thank you for viewing the detailed overview of OptiNose's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


OptiNose (OptiNose) Business Description

Traded in Other Exchanges
Address
1020 Stony Hill Road, Suite 300, Yardley, PA, USA, 19067
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.
Executives
Marino Michael F Iii officer: Chief Legal Officer & Corp Sec C/O NUPATHE, INC., 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Ramy A Mahmoud officer: President & COO 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Peter K Miller director, officer: Chief Executive Officer C/O INTERNET CAPITAL GROUP, 690 LEE ROAD, SUITE 310, WAYNE PA 19087
Mvm Partners, Llc 10 percent owner OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Michele Janis officer: Acting Chief Financial Officer 1020 STONY HILL ROAD, YARDLEY PA 19067
Victor M Clavelli officer: Chief Commercial Officer 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Paul Jr. Spence officer: Chief Commercial Officer 1507 POWNAL DRIVE, YARDLEY PA 19067
Anthony J Krick officer: Chief Accounting Officer 1020 STONY HILL ROAD, YARDLEY PA 19067
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Kyle Dempsey director OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Eric Bednarski director OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Partners Llp Mvm 10 percent owner 30 ST. GEORGE STREET, LONDON X0 W1S SFH
Keith A. Goldan officer: Chief Financial Officer 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Joseph C Scodari director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080